Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets
- PMID: 23530096
- DOI: 10.1200/JCO.2012.44.3747
Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets
Abstract
Purpose: Integration of numerous prognostic variables not included in the conventional staging of retroperitoneal soft tissue sarcomas (RPS) is essential in providing effective treatment. The purpose of this study was to build a specific nomogram for predicting postoperative overall survival (OS) and disease-free survival (DFS) in patients with primary RPS.
Patients and methods: Data registered in three institutional prospective sarcoma databases were used. We included patients with primary localized RPS resected between 1999 and 2009. Univariate (Kaplan and Meier plots) and multivariate (Cox model) analyses were carried out. The a priori chosen prognostic covariates were age, tumor size, grade, histologic subtype, multifocality, quality of surgery, and radiation therapy. External validation was performed by applying the nomograms to the patients of an external cohort. The model's discriminative ability was estimated by means of the bootstrap-corrected Harrell C statistic.
Results: In all, 523 patients were identified at the three institutions (developing set). At a median follow-up of 45 months (interquartile range, 22 to 72 months), 171 deaths were recorded. Five- and 7-year OS rates were 56.8% (95% CI, 51.4% to 62.6%) and 46.7% (95% CI, 39.9% to 54.6%. Two hundred twenty-one patients had disease recurrence. Five- and 7-year DFS rates were 39.4% (95% CI, 34.5% to 45.0%) and 35.7% (95% CI, 30.3% to 42.1%). The validation set consisted of 135 patients who were identified at the fourth institution for external validation. The bootstrap-corrected Harrell C statistics for OS and DFS were 0.74 and 0.71 in the developing set and 0.68 and 0.69 in the validating set.
Conclusion: These nomograms accurately predict OS and DFS. They should be used for patient counseling in clinical practice and stratification in clinical trials.
Comment in
-
Sarcoma: primary retroperitoneal sarcoma-predicting survival.Nat Rev Clin Oncol. 2013 Jun;10(6):309-10. doi: 10.1038/nrclinonc.2013.73. Epub 2013 May 7. Nat Rev Clin Oncol. 2013. PMID: 23648823 No abstract available.
-
Retroperitoneal Sarcoma: Setting the Stage for Treatment Strategies Tailored to Histologic Subtype and Other Patient and Tumor Factors.Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):292-295. doi: 10.1016/j.ijrobp.2017.05.021. Int J Radiat Oncol Biol Phys. 2017. PMID: 28871972 No abstract available.
Similar articles
-
External validation of a multi-institutional retroperitoneal sarcoma nomogram.Cancer. 2016 May 1;122(9):1417-24. doi: 10.1002/cncr.29931. Epub 2016 Feb 24. Cancer. 2016. PMID: 26916507
-
Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG.Clin Cancer Res. 2019 Apr 15;25(8):2664-2671. doi: 10.1158/1078-0432.CCR-18-2700. Epub 2019 Feb 5. Clin Cancer Res. 2019. PMID: 30723141
-
Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms.Eur J Cancer. 2021 Nov;157:291-300. doi: 10.1016/j.ejca.2021.08.008. Epub 2021 Sep 20. Eur J Cancer. 2021. PMID: 34555648
-
Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution.Ann Surg. 1998 Sep;228(3):355-65. doi: 10.1097/00000658-199809000-00008. Ann Surg. 1998. PMID: 9742918 Free PMC article. Review.
-
Contemporary reappraisal of the efficacy of adjuvant chemotherapy in resected retroperitoneal sarcoma: Evidence from a nationwide clinical oncology database and review of the literature.Surg Oncol. 2017 Jun;26(2):117-124. doi: 10.1016/j.suronc.2017.01.008. Epub 2017 Feb 2. Surg Oncol. 2017. PMID: 28577717 Review.
Cited by
-
Development of a Multi-Institutional Prediction Model for Three-Year Survival Status in Patients with Uterine Leiomyosarcoma (AGOG11-022/QCGC1302 Study).Cancers (Basel). 2021 May 14;13(10):2378. doi: 10.3390/cancers13102378. Cancers (Basel). 2021. PMID: 34069227 Free PMC article.
-
Retroperitoneal Sarcomas: a Current Review on Management.Indian J Surg Oncol. 2022 Sep;13(3):542-558. doi: 10.1007/s13193-022-01520-y. Epub 2022 Feb 21. Indian J Surg Oncol. 2022. PMID: 36187536 Free PMC article. Review.
-
Unsupervised versus Supervised Identification of Prognostic Factors in Patients with Localized Retroperitoneal Sarcoma: A Data Clustering and Mahalanobis Distance Approach.Biomed Res Int. 2018 Apr 23;2018:2786163. doi: 10.1155/2018/2786163. eCollection 2018. Biomed Res Int. 2018. PMID: 29850497 Free PMC article.
-
Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy.Cancer Med. 2014 Jun;3(3):603-12. doi: 10.1002/cam4.209. Epub 2014 Feb 27. Cancer Med. 2014. PMID: 24574357 Free PMC article.
-
Long-term Oncologic Outcomes After Neoadjuvant Radiation Therapy for Retroperitoneal Sarcomas.Ann Surg. 2015 Jul;262(1):163-70. doi: 10.1097/SLA.0000000000000840. Ann Surg. 2015. PMID: 25185464 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical